Analysts: Boston Scientific could lose $470 million on defib recall, might sell off assets

April 1, 2010 by MassDevice staff

One analyst forecasts a $470 million loss over the next two years on Boston Scientific's defibrillator recall, while others say the company could look to sell off its pain management or neurovascular intervention units to cover the gap.

BSX logo

Boston Scientific Corp. (NYSE:BSX) could look to sell of a business unit to make up for a projected $470 million shortfall stemming from the shutdown of its defibrillator operation, according to analysts.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp